Renata Kobayashi

Prof. Renata Kobayashi

Departamento de Microbiologia, Universidade Estadual de Londrina, Londrina, Brazil
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2016 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
SSSara Scandorieiro
Sara Scandorieiro
LCLarissa C. de Camargo
Larissa C. de Camargo
CLCesar A. C. Lancheros
Cesar A. C. Lancheros
SYSueli F. Yamada-Ogatta
Sueli F. Yamada-Ogatta
CNCelso V. Nakamura
Celso V. Nakamura
RKRenata Kobayashi
Renata Kobayashi
Bacterial resistance to conventional antibiotics has become a clinical and public health problem, making therapeutic decisions more challenging. Plant compounds and nanodrugs have been proposed as potential antimicrobial alternatives. Studies have shown that oregano (Origanum vulgare) essential oil (OEO) and silver nanoparticles have potent antibacterial activity, also against multidrug-resistant strains; however, the strong organoleptic characteristics of OEO and the development of resistance to these metal nanoparticles can limit their use. This study evaluated the antibacterial effect of a two-drug combination of biologically synthesized silver nanoparticles (bio-AgNP), produced by Fusarium oxysporum, and OEO against Gram-positive and Gram-negative bacteria, including multidrug-resistant strains. OEO and bio-AgNP showed bactericidal effects against all seventeen strains tested, with minimal inhibitory concentrations (MIC) ranging from 0.298 to 1.193 mg/mL and 62.5 to 250 µM, respectively. Time-kill curves indicated that OEO acted rapidly (within 10 min), while the metallic nanoparticles took 4 h to kill Gram-negative bacteria and 24 h to kill Gram-positive bacteria. The combination of the two compounds resulted in a synergistic or additive effect, reducing their MIC values and reducing the time of action compared to bio-AgNP used alone, i.e., 20 min for Gram-negative bacteria and 7 h for Gram-positive bacteria. Scanning electron microscopy (SEM) revealed similar morphological alterations in Staphylococcus aureus (non-methicillin-resistant S. aureus, non-MRSA) cells exposed to three different treatments (OEO, bio-AgNP and combination of the two), which appeared cell surface blebbing. Individual and combined treatments showed reduction in cell density and decrease in exopolysaccharide matrix compared to untreated bacterial cells. It indicated that this composition have an antimicrobial activity against S. aureus by disrupting cells. Both compounds showed very low hemolytic activity, especially at MIC levels. This study describes for the first time the synergistic and additive interaction between OEO and bio-AgNP produced by F. oxysporum against multidrug-resistant bacteria, such as MRSA, and β-lactamase- and carbapenemase-producing Escherichia coli and Acinetobacter baumannii strains. These results indicated that this combination can be an alternative in the control of infections with few or no treatment options.

6 June 2019 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
PDF file
ADAna Paula Daga
Ana Paula Daga
VKVanessa Lumi Koga
Vanessa Lumi Koga
JSJoão Gabriel Material Soncini
João Gabriel Material Soncini
CMCaroline Martins de Matos
Caroline Martins de Matos
MPMarcia Regina Eches PERUGINI
Marcia Regina Eches PERUGINI
EVEliana Carolina Vespero
Eliana Carolina Vespero
Extraintestinal pathogenic Escherichia coli (ExPEC) isolates are responsible for many bloodstream infections. The aim of this study was to characterize E. coli isolated from the bloodstreams of patients (n = 48) at the University Hospital in Brazil. Epidemiological data were obtained through the analysis of medical records and laboratory tests. By PCR analysis, we investigated the presence of virulence factors (VFs), pathogenicity islands (PAIs), extended-spectrum β-lactamase (ESBL), phylogenetic classifications (A, B1, B2, C, D, E, and F) and molecular genotype by enterobacterial repetitive intergenic consensus-polymerase chain reaction (ERIC-PCR). The mortality analysis showed that 33.3% of the deaths were associated with bacteraemia due to E. coli infections; in addition, an age between 60 and 75 years (p < 0.001; OR = 6.3[2.1–18.9]) and bacteraemia with an abdominal origin (p = 0.02; OR = 5[1.2–20.5]) were risk factors for the severity of the infection. Additionally, the presence of the afa gene was associated with mortality due to E. coli bacteraemia (p = 0.027; OR = 11.4[1.5–85.7]). Immunosuppression (27.1%), intestinal diseases (25.0%) and diabetes (18.8%), were prevalent among patients, and most of the bacteraemia cases were secondary to urinary tract infections (50.0%). The serum resistance gene traT was present in 77.1% of isolates, group capsular 2 (kpsMT II) was present in 45.8% and the K5 capsule was present in 20.8% of isolates. The isolates also showed a high prevalence for the siderophore yersiniabactina (fyuA) (70.8%) and PAI IV536 (77.1%). Phylogenetic analysis showed that group B2 (45.8%) was the most prevalent, and was the phylogroup that had a higher prevalence of VFs and PAIs. However, in this study, a considerable number of isolated bacteria were classified as group B1 (18.8%) and as group E (14.6%). Eight (16.7%) isolates were resistant to third and fourth generation cephalosporin and group CTX-M-1 (CTX-M-15) was the most prevalent ESBL type. The molecular genotyping showed two clonal lineages and several isolates that were not related to each other. This study provides additional information on the epidemiological and molecular characteristics of E. coli bloodstream infections in Brazil.

1 January 2013 in Annals of Clinical Microbiology and Antimicrobials
Verified
Journal Article
Open access
PDF file
VCViviane F Cardozo
Viviane F Cardozo
Admilton Gonçalves de OliveiraAdmilton Gonçalves de Oliveira
Admilton Gonçalves de Oliveira
ENErick K Nishio
Erick K Nishio
MPMarcia Regina Eches PERUGINI
Marcia Regina Eches PERUGINI
CACélia Gtj Andrade
Célia Gtj Andrade
GNGerson Nakazato
Gerson Nakazato
Background: The emergence of multidrug-resistant bacteria is a world health problem. Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA) strains, is one of the most important human pathogens associated with hospital and community-acquired infections. The aim of this work was to evaluate the antibacterial activity of a Pseudomonas aeruginosa-derived compound against MRSA strains. Methods: Thirty clinical MRSA strains were isolated, and three standard MRSA strains were evaluated. The extracellular compounds were purified by vacuum liquid chromatography. Evaluation of antibacterial activity was performed by agar diffusion technique, determination of the minimal inhibitory concentration, curve of growth and viability and scanning electron microscopy. Interaction of an extracellular compound with silver nanoparticle was studied to evaluate antibacterial effect. Results: The F3 (ethyl acetate) and F3d (dichloromethane- ethyl acetate) fractions demonstrated antibacterial activity against the MRSA strains. Phenazine-1-carboxamide was identified and purified from the F3d fraction and demonstrated slight antibacterial activity against MRSA, and synergic effect when combined with silver nanoparticles produced by Fusarium oxysporum. Organohalogen compound was purified from this fraction showing high antibacterial effect. Using scanning electron microscopy, we show that the F3d fraction caused morphological changes to the cell wall of the MRSA strains. Conclusions: These results suggest that P. aeruginosa-produced compounds such as phenazines have inhibitory effects against MRSA and may be a good alternative treatment to control infections caused by MRSA.

1 October 2014 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
VCViviane F. Cardozo
Viviane F. Cardozo
CLCesar A.C. Lancheros
Cesar A.C. Lancheros
ANAdélia M. Narciso
Adélia M. Narciso
EVElaine C.S. Valereto
Elaine C.S. Valereto
RKRenata Kobayashi
Renata Kobayashi
GNGerson Nakazato
Gerson Nakazato

1 October 2013 in Veterinary Microbiology
Verified
Journal Article
Closed access
JPJuan Puño-Sarmiento
Juan Puño-Sarmiento
LMLeonardo Medeiros
Leonardo Medeiros
CCCarolina Chiconi
Carolina Chiconi
FMFernando Martins
Fernando Martins
JPJacinta Pelayo
Jacinta Pelayo
GNGerson Nakazato
Gerson Nakazato

1 June 2017 in Acta Tropica
Verified
Journal Article
Open access
German A. IslanGerman A. Islan
German A. Islan
MDMarcela Durán
Marcela Durán
Maximiliano Luis CacicedoMaximiliano Luis Cacicedo
Maximiliano Luis Cacicedo
GNGerson Nakazato
Gerson Nakazato
RKRenata Kobayashi
Renata Kobayashi
NDNelson Duran
Nelson Duran
The study of neglected diseases has not received much attention, especially from public and private institutions over the last years, in terms of strong support for developing treatment for these diseases. Support in the form of substantial amounts of private and public investment is greatly needed in this area. Due to the lack of novel drugs for these diseases, nanobiotechnology has appeared as an important new breakthrough for the treatment of neglected diseases. Recently, very few reviews focusing on filiarasis, leishmaniasis, leprosy, malaria, onchocerciasis, schistosomiasis, trypanosomiasis, and tuberculosis, and dengue virus have been published. New developments in nanocarriers have made promising advances in the treatment of several kinds of diseases with less toxicity, high efficacy and improved bioavailability of drugs with extended release and fewer applications. This review deals with the current status of nanobiotechnology in the treatment of neglected diseases and highlights how it provides key tools for exploring new perspectives in the treatment of a wide range of diseases.